Cormorant Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Cormorant Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.1M	Sell	750,000 -200,000	-21%	-$17.5M	3.75%	10
2026 Q1	$79.7M	Buy	+950,000	New	+$55M	4%	10
2021 Q4	–	Sell	-29,888	Closed	-$3.48M	–	81
2021 Q3	$3.48M	Hold	29,888	–	–	0.14%	77
2021 Q2	$4.68M	Sell	29,888 -7,612	-20%	-$1.4M	0.16%	83
2021 Q1	$7.1M	Buy	+37,500	New	+$6.31M	0.16%	84

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Cormorant Asset Management's DNTH Position: Q2 2026 in Review

Cormorant Asset Management reduced its Dianthus Therapeutics (DNTH) stake by 21% in Q2 2026, selling an estimated $17.5M and leaving 750,000 shares worth $73.1M. The position accounts for 3.75% of the portfolio, ranked #10.

Cormorant Asset Management first reported a position in DNTH in Q1 2021 and has held it in 5 quarters since. The position peaked at $79.7M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Cormorant Asset Management held 750,000 shares of Dianthus Therapeutics worth $73.1M as of Q2 2026.
Cormorant Asset Management sold 200,000 Dianthus Therapeutics shares in Q2 2026, an estimated $17.5M.
Dianthus Therapeutics made up 3.75% of Cormorant Asset Management's portfolio in Q2 2026, its #10 holding.
Cormorant Asset Management first reported a position in Dianthus Therapeutics in Q1 2021 and has held it in 5 quarters since.
Cormorant Asset Management's Dianthus Therapeutics position peaked at $79.7M in Q1 2026.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.